ArticleBiometals : an international journal on the role of metal ions in biology, biochemistry, and medicine2026
Conjugates of desferrioxamine with 5-aminolevulinic or γ-aminobutyric acid: synthesis, theoretical studies, iron-chelating ability, and penetration in human Caco-2 cells.
Article in Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Iron overload (IO) is a harmful condition in humans that promotes oxidative damage to DNA and lipids. As IO has been associated with the onset of neurodegenerative diseases (NDs), chelation therapy has been extensively used for treating IO and considered potentially suitable for NDs treatment. Desferrioxamine (DFO) presents high affinity and selectivity for iron(III), however, its clinical use as chelator is limited due to its low cell permeability. To circumvent this limitation, synthetic routes and conditions were selected for conjugating DFO to 5-aminolevulinic acid (5-ALA) or γ-aminobutyric acid (GABA), non-proteinogenic amino acids previously reported as permeable to the blood-brain barrier (BBB). Once obtained and purified, the conjugates 5-ALA-DFO and GABA-DFO were characterized by LC/ESI-MS and
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.